Advertisement
Australia markets closed
  • ALL ORDS

    8,015.80
    +72.20 (+0.91%)
     
  • AUD/USD

    0.6647
    +0.0034 (+0.51%)
     
  • ASX 200

    7,778.10
    +77.80 (+1.01%)
     
  • OIL

    80.76
    +0.43 (+0.54%)
     
  • GOLD

    2,334.60
    +5.60 (+0.24%)
     
  • Bitcoin AUD

    97,477.90
    -637.17 (-0.65%)
     
  • CMC Crypto 200

    1,345.26
    -44.15 (-3.18%)
     

Dynavax to Present at Upcoming Investor Conferences

EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June:

(PRNewsfoto/Dynavax Technologies)
(PRNewsfoto/Dynavax Technologies)
  • William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 1:20 p.m. CT

  • Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 at 4:00 p.m. ET

The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations.

ADVERTISEMENT

About Dynavax

Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn and Twitter.

For Investors/Media:
Paul Cox
pcox@dynavax.com 
510-665-0499

Nicole Arndt
narndt@dynavax.com,  510-665-7264

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-upcoming-investor-conferences-302157153.html

SOURCE Dynavax Technologies